### NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

# **Single Technology Appraisal (STA)**

## Pemetrexed for the first line treatment of non small cell lung cancer

### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors  Eli Lilly & Co. (pemetrexed)  Patient/carer groups  Afiya Trust  Age Concern England  Black Health Agency  Breathe Easy  British Ethnic Health Awareness	<ul> <li>Commentators (no right to submit or appeal)</li> <li>General         <ul> <li>Age Concern Cymru</li> <li>Board of Community Health Councils in Wales</li> </ul> </li> <li>British National Formulary</li> <li>Cancer Care Cymru</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Medicines and Healthcare products</li> </ul>
Foundation (BEHAF)  British Lung Foundation  CANCERactive  Cancerbackup  Cancer Black Care  Cancer Equality  Cancer Voices  Chinese National Healthy Living Centre  Confederation of Indian Organisations	<ul> <li>Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Public Health Service for Wales</li> <li>NHS Alliance</li> <li>NHS Confederation</li> <li>NHS Purchasing and Supply Agency</li> <li>NHS Quality Improvement Scotland</li> <li>Scottish Medicines Consortium</li> </ul>
<ul> <li>Counsel and Care</li> <li>Equalities National Council</li> <li>Helen Rollason Heal Cancer Charity</li> <li>Help the Aged</li> <li>Macmillan Cancer Support</li> <li>Maggie's Centres</li> <li>Marie Curie Cancer Care</li> <li>Muslim Council of Great Britain</li> <li>Muslim Health Network</li> <li>National Cancer Alliance</li> <li>National Council for Palliative Care</li> <li>Roy Castle Lung Cancer Foundation</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Sue Ryder Care</li> </ul>	<ul> <li>Comparator manufacturers</li> <li>AAH Pharmaceuticals (vinorelbine)</li> <li>Bristol Myers Squibb (paclitaxel)</li> <li>Hospira UK (vinorelbine, paclitaxel)</li> <li>Eli Lilly &amp; Co. (gemcitabine)</li> <li>Medac UK (vinorelbine)</li> <li>Pierre Fabre (vinorelbine)</li> <li>PLIVA Pharma (paclitaxel)</li> <li>Sanofi Aventis (docetaxel)</li> <li>Teva UK (paclitaxel)</li> <li>Wockhardt UK (vinorelbine, paclitaxel)</li> </ul>

National Institute for Health and Clinical Excellence

Matrix for the appraisal of pemetrexed for the first line treatment of non small cell lung cancer Issue date: October 2008

Consultees	Commentators (no right to submit or
	appeal)
<ul> <li>Tenovus Cancer Information Centre</li> <li>UK Lung Cancer Coalition</li> <li>Professional groups</li> <li>Association of Cancer Physicians</li> <li>Association of Respiratory Nurse Specialists</li> <li>British Association for Services to the Elderly</li> <li>British Geriatrics Society</li> <li>British Oncological Association (BOA)</li> <li>British Psychosocial Oncology Society</li> <li>British Thoracic Society (Lung Cancer and Mesothelioma Working party)</li> <li>Cancer Networks Pharmacists Forum</li> <li>Cancer Research UK</li> <li>General Practice Airways Group</li> <li>National Lung Cancer Forum for Nurses</li> <li>Royal College of General Practitioners</li> <li>Royal College of Physicians, Medical Oncology Joint Special Committee</li> <li>Royal College of Physicians' Intercollegiate Lung Cancer Group</li> <li>Royal College of Radiologists</li> <li>Royal College of Radiologists</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>United Kingdom Clinical Pharmacy Association</li> <li>United Kingdom Oncology Nursing Society</li> <li>Others</li> </ul>	<ul> <li>Relevant research groups</li> <li>British Thoracic Oncology Group</li> <li>Institute of Cancer Research</li> <li>MRC CTU - Lung Cancer and Mesothelioma Group</li> <li>National Cancer Research Institute</li> <li>National Cancer Research Network</li> <li>National Institute for Health Research</li> <li>Policy Research Institute on Ageing and Ethnicity</li> <li>Research Institute for the Care of Older People</li> <li>UK Clinical Research Network</li> <li>Evidence Review Group</li> <li>Liverpool Reviews &amp; Implementation Group, University of Liverpool</li> <li>National Coordinating Centre for Health Technology Assessment</li> <li>Associated Guideline Groups</li> <li>National Collaborating Centre for Cancer</li> <li>Associated Public Health Groups</li> <li>none</li> </ul>
<ul><li>Department of Health</li><li>Salford Teaching PCT</li></ul>	
<ul><li>Southampton City PCT</li><li>Welsh Assembly Government</li></ul>	

**Appendix B** 

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

#### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.